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ABSTRACT
Background. Patients with curable esophageal cancer
(EC) who proceed beyond the original Chemoradiotherapy
for Oesophageal Cancer Followed by Surgery Study
(CROSS) eligibility criteria are also treated with neoadju-
vant chemoradiotherapy (nCRT). This study assessed the
effect that extending the CROSS eligibility criteria for
nCRT has on treatment-related toxicity and overall survival
(OS) in EC.
Methods. The study enrolled 161 patients with locally
advanced EC (T1N1-3/T2-4aN0-3/M0) treated with the
CROSS schedule followed by esophagectomy. Group 1
consisted of 89 patients who met the CROSS criteria, and
group 2 consisted of 72 patients who met the extended
eligibility criteria, i.e. a tumor length greater than 8 cm
(n = 24), more than 10% weight loss (n = 35), more than
2–4 cm extension in the stomach (n = 21), celiac lymph
node metastasis (n = 13), and/or age over 75 years
(n = 2). The study assessed the differences in nCRT-as-
sociated toxicity [National Cancer Institute’s Common
Terminology Criteria for Adverse Events (CTCAE) grade
C 3] and 90-day postoperative mortality. Moreover, the
prognostic value for OS was assessed with multivariate
Cox regression analysis.
Results. No difference was found in nCRT-associated
toxicity (P = 0.117), postoperative complications
(P = 0.783), and 90-day mortality (P = 0.492). The OS
differed significantly (P = 0.004), with a median of
37.3 months [95% confidence interval (CI),
10.4–64.2 months] for group 1 and 17.2 months (95% CI
13.8–20.7 months) for group 2. Pathologic N stage
(P = 0.023), pathologic T stage (P = 0.043), and group 2
(P = 0.008) were independent prognostic factors for OS.
Conclusions. Extension of the CROSS study eligibility
criteria for nCRT did not affect nCRT-associated toxicity,
postoperative complications, and postoperative mortality,
but was prognostic for OS.
Neoadjuvant chemoradiotherapy (nCRT) according to the
Chemoradiotherapy for Oesophageal Cancer Followed by
Surgery Study (CROSS) schedule (carboplatin/paclitaxel and
41.4 Gy radiotherapy) followed by a radical surgical resec-
tion is the gold standard for locally advanced esophageal
cancer (EC) in the Netherlands.1 This nCRT scheme in-
creased the 5-year overall survival (OS) by 10–13% while the
postoperative complication rate did not increase.1,2
Patients with a potentially curative resectable EC who
do not meet the original CROSS study inclusion criteria are
currently also treated with nCRT, i.e. including patients
aged over 75 years and those with a tumor length[8 cm, a
tumor that extends[2–4 cm into the gastric cardia, and/or
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[10% body weight loss. Moreover, the original CROSS
study excluded patients with celiac lymph node metastases
because these nodes were previously classified as distant
metastases (M1a) in the American Joint Committee on
Cancer (AJCC) TNM 6th edition.3 The currently used 7th
edition of the AJCC TNM classifies celiac node involve-
ment as regional metastasis (N1–3), and these patients are
consequently treated with nCRT.4
Besides a small Dutch study, which found that the
extended inclusion criteria tumor length [8 cm and age
over 75 years did not influence the complication rate, no
study has assessed the influence of extension of all CROSS
eligibility criteria for nCRT on toxicity and survival.5 This
study was designed to assess the effect of extended eligi-
bility criteria for treatment with nCRT on the toxicity and
mortality (\90 days posttreatment) of EC patients. Fur-
thermore, we assessed the difference in disease-free
survival (DFS) and OS between patients that met the




Data for this retrospective study were obtained from a
prospectively maintained database and the study was con-
ducted according to the national guidelines and the rules
approved by the local ethics board. All patients with locally
advanced EC (TNM7: T1N1-3/T2-4aN0-3/M0) who
underwent nCRT according to the CROSS schedule fol-
lowed by surgery between 2005 and 2015 at the University
Medical Center Groningen were eligible for inclusion.
All patients included in the study had a histologically
proven adenocarcinoma or squamous cell carcinoma of the
esophagus or esophagogastric junction. In addition, the
patients had an adequate hematologic, renal, hepatic, and
pulmonary function, together with a World Health Orga-
nization (WHO) performance status of 2 or lower.
Based on the aforementioned criteria, 177 patients were
eligible for inclusion. A total of 16 patients were excluded
because of concurrent malignancies (n = 3), previous
malignancies within 5 years before treatment (n = 3),
missing blood values (n = 7), progressive disease due to
distant metastases present on the restaging PET/CT
(n = 2), or a prolonged interval ([6 months) between
nCRT and surgery (n = 1). Consequently, 161 patients
were included in the study.
METHODS
The patients were divided in two groups. Group 1
consisted of 89 patients who met the original CROSS study
inclusion criteria, and group 2 consisted of 72 patients with
the extended nCRT criteria. Group 2 included 24 patients
with a tumor longer than 8 cm, 35 patients with more than
10% weight loss, 21 patients with more than 2–4 cm tumor
extension in the gastric cardia, 13 patients with celiac
lymph node metastasis, and 2 patients older than 75 years.
The primary objective was to assess the difference in
nCRT-related toxicity (grade C 3) between group 1 and 2.
All treatment complications and severity were measured
according to the National Cancer Institute’s Common
Terminology Criteria for Adverse Events (CTCAE) version
4.0 grading scale.6 The secondary outcomes were the dif-
ference in postoperative complications, postoperative
mortality (30- and 90-day rates), DFS, and OS. DFS was
defined as the time between the start of nCRT and the date
of tumor recurrence and OS as the time between the start of
nCRT and the date of death or last follow-up.
In addition, we compared OS of the extended CROSS
group with a reference dCRT group using a multivariate
Cox regression analysis containing all confounders (gen-
der, cTN stage, tumor location, tumor length, histology,
and age).
Staging
All patients were staged with endoscopic ultrasonogra-
phy combined with a fine-needle aspiration biopsy when
indicated, computed tomography (CT) of the chest and
abdomen, and 18-F-fluorodeoxyglucose (FDG) positron
emission tomography (PET) or integrated FDG-PET/CT.
When indicated, additional imaging was performed.
Patients were staged according to the 7th edition of the
tumor-node-metastasis (TNM) classification.4
Treatment
All patients received nCRT according to the CROSS
schedule, consisting of five weekly intravenous adminis-
trations of carboplatin [area under the curve (AUC) 2 mg/
ml/min] and paclitaxel (50 mg/m2), as well as concurrent
external beam radiotherapy (41.4 Gy/23 fractions) 5 days
per week.1,2 After nCRT, either a radical transthoracic or
minimally invasive esophagectomy was performed, with en
bloc dissection of mediastinal and abdominal lymph nodes.
Definitive chemoradiotherapy (dCRT) consisted of either
carboplatin/paclitaxel (AUC 2 and 50 mg/m2) or cisplatin
and fluorouracil (Cis-5FU, 75 mg/m2 and 1 g/m2) com-
bined with radiotherapy (40–60 Gy in 30 fractions).
Pathology
Resected specimens were pathologically assessed
according to a standard protocol on histologic subtype,
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Male 71 (79.8) 57 (79.2) 0.924a
Age (years), median (IQR) 63 (58–67) 64 (57–69) 0.299b
WHO/ECOG performance status 0.843a
0–1 85 (95.5) 64 (88.9)
2 0 (0.0) 0 (0.0)
Missing 4 (4.5) 8 (11.1)
Comorbidities total 44 (49.4) 38 (52.8) 0.673a
Cardiovascular 34 (38.2) 28 (38.9) 0.798a
Pulmonary 3 (3.4) 1 (1.4)
Cardiovascular and pulmonary 5 (5.6) 6 (8.3)
Other 2 (2.2) 3 (4.2)
No comorbidities 45 (50.6) 34 (47.2)
Histology 0.095a
Adenocarcinoma 79 (88.8) 57 (79.2)
Squamous cell carcinoma 10 (11.2) 15 (20.8)
Tumor location
Middle esophagus 7 (7.9) 5 (6.9) 0.005a
Distal esophagus 76 (85.4) 49 (68.1)
GEJ 6 (6.7) 18 (25.0)
Tumor length (cm), median (IQR) 5.0 (3.0–6.0) 6.5 (5.0–9.0) 0.000b
cT stage 0.000a
T1 0 (0.0) 2 (2.8)
T2 25 (28.1) 5 (6.9)
T3 63 (70.8) 56 (77.8)
T4a 1 (1.1) 9 (12.5)
cN stage 0.024a
N0 22 (24.7) 7 (9.7)
N1 38 (42.7) 30 (41.7)
N2 27 (30.3) 29 (40.3)
N3 2 (2.2) 6 (8.3)
ypT stage 0.525a
CR 15 (16.9) 13 (18.1)
T0 4 (4.5) 2 (2.8)
T1 17 (19.1) 8 (11.1)
T2 11 (12.4) 9 (12.5)
T3 42 (47.2) 40 (55.6)
ypN stage 0.706a
N0 57 (64.0) 44 (61.1)
N1 18 (20.2) 16 (22.2)
N2 11 (12.4) 7 (9.7)
N3 3 (3.4) 5 (6.9)
Perineural growth 15 (16.9) 18 (25.0) 0.204a
Lymphangio-invasion 14 (15.7) 19 (26.4) 0.097a
LN ratio ([0.2 LN?) 12 (13.5) 11 (15.3) 0.747a
Extended CROSS Eligibility Criteria in EC
radicality of the resection margins (proximal, distal, and
circumferential), pathologic T (ypT) stage, pathologic
lymph node (ypN) stage, tumor location, perineural
growth, and lymphangio-invasion.
Follow-up Evaluation
According to the standard protocol, patients were seen
every 3 months during the first year, every 4 and 6 months
during the second and third year, and subsequently once
every succeeding year until 10 years after treatment. Dur-
ing the follow-up, tumor recurrence and/or cause of death
was accurately described. Tumor recurrence was proven
either pathologically or radiologically.
Statistical Analysis
Differences in patient characteristics and complications
were assessed using the Chi square test or the likelihood
ratio test for categorical variables and the Mann–Whitney
U test for non-normally distributed variables.
Kaplan–Meier curves were used to display the DFS and
OS. Univariate Cox regression analysis was performed on
all possible prognostic factors for both DFS and OS. All
factors with a P value lower than 0.10 in the univariate Cox
regression analysis were included in the multivariate Cox
regression analysis. A P value lower than 0.05 was con-
sidered statistically significant. All statistical analyses were
performed with IBM SPSS Statistics for Windows, version
22.0 (IBM Corp., Armonk, NY, USA).
RESULTS
Patients’ Characteristics
The characteristics of the patients are summarized in
Table 1. The group 2 patients (n = 72) were more likely to
have a tumor involving the gastroesophageal (GE) junction
(P = 0.005), a higher clinical T stage (cT; P = 0.000), and
a higher clinical N stage (P = 0.024) than the group 1
patients (n = 89). In addition, significantly more patients
in group II died (P = 0.004) and the follow-up period was
significantly shorter for group 2, with a median follow-up
of 16.2 months [interquartile range (IQR)
9.2–40.3 months] compared with 23.2 months (IQR
11.8–52.9 months) for group 1 (P = 0.037).
In group 1 and 2 respectively 79.8 and 80.6% of the
patients were able to complete the entire nCRT regimen
(Table 2). Of the patients in group 2, 12 (16.7%) fulfilled
two extended criteria, 4 (5.6%) fulfilled three criteria, and 1
(1.4%) fulfilled four criteria. The presence of two or more
extended eligibility criteria within a patient (n = 17) ver-
sus only one extended criterion (n = 55) did not influence
the OS (P = 0.642) or DFS (P = 0.198).
Toxicity and Postoperative Survival
Table 2 displays the distribution of nCRT toxicity,
postoperative complications, and postoperative mortality
(30- and 90-day rates) between the two groups. A total of
48 patients (29.8%) experienced severe toxicity (gra-
de C 3) or received a blood transfusion. The total toxicity
rates did not differ between the two groups (P = 0.117),
nor did the number of postoperative complications (data
shown in Table 2).
Although more patients in group 2 (n = 7, 9.7%) died
within 90 days after surgery than in group 1 (n = 6, 6.7%),
this difference was not significant (P = 0.492). In addition,
the 30-day postoperative mortality did not differ between
the two groups (P = 0.486), with a 30-day mortality rate of
2.2% (n = 2) in group 1 and 4.2% (n = 3) in group 2.
Overall Survival
Figure 1 displays the Kaplan–Meier curves with the OS
and DFS for both group 1 and 2. The OS differed signifi-
cantly between the two groups (P = 0.004: Fig. 1a), with a
median of 37.3 months (95% confidence interval [CI]
10.4–64.2 months) in group 1 and 17.2 months (95% CI









Follow-up (months), median (IQR) 23.2 (11.8–52.9) 16.2 (9.2–40.3) 0.037b
IQR interquartile range, WHO World Health Organization, ECOG Eastern Cooperative Oncology Group, GEJ gastroesophageal junction, cT
clinical T stage, cN clinical N stage, ypT pathologic T stage, ypN pathologic lymph node stage, LN lymph node
a Likelihood ratio
b Mann–Whitney U test
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Completed nCRT 71 (79.8) 58 (80.6) 0.902a
Hematologic toxicity 0.068a
Thrombocytopenia–overall
Not applicable 26 (29.2) 28 (38.9)
Grade 1 54 (60.7) 43 (59.7)
Grade 2 8 (9.0) 1 (1.4)
Grade 3 1 (1.1) 0 (0.0)
Leukopenia–overall 0.338a
Not applicable 15 (16.9) 20 (27.8)
Grade 1 34 (38.2) 21 (29.2)
Grade 2 26 (29.2) 19 (26.4)
Grade 3 13 (14.6) 12 (16.7)
Grade 4 1 (1.1) 0 (0.0)
Blood transfusion 0.417a
0 87 (97.8) 67 (93.1)
1 0 (0.0) 1 (1.4)
2 1 (1.1) 1 (1.4)
3 1 (1.1) 2 (2.8)
4 0 (0.0) 1 (1.4)
Other nCRT complications (grade C 3)
Anemia 0 (0.0) 0 (0.0) NAa
Bleeding 0 (0.0) 1 (1.4) 0.203a
Nausea 3 (3.4) 4 (5.6) 0.501a
Fatigue 1 (1.1) 1 (1.4) 0.880a
Neurotoxic 0 (0.0) 2 (2.8) 0.071a
Diarrhea 0 (0.0) 1 (1.4) 0.203a
Esophagitis 2 (2.2) 5 (6.9) 0.144a
Grade C 3 or blood transfusion 22 (24.7) 26 (36.1) 0.117a
Postoperative complications
Pulmonary (all grades)b 49 (55.1) 38 (52.8) 0.773a
Pneumonia 41 (46.1) 28 (38.9) 0.360a
Respiratory insufficiency 19 (21.3) 13 (18.1) 0.602a
Pulmonary embolism 2 (2.2) 0 (0.0) 0.122a
Cardiac (all grades)c 26 (29.2) 22 (30.6) 0.835a
Arrhythmia 25 (28.1) 22 (30.6) 0.732a
Myocardial infarction 1 (1.4) 0 (0.0) 0.273a
Sepsis 8 (9.0) 6 (8.3) 0.883a
Postoperative bleeding 2 (2.2) 1 (1.4) 0.678a
Chylothorax 11 (12.4) 3 (4.2) 0.057a
Cardiac arrest 2 (2.2) 3 (4.2) 0.486a
Esophageal anastomotic leak 8 (9.0) 12 (16.7) 0.143a
Renal failure 2 (2.2) 4 (5.6) 0.276a
IIeus 6 (6.7) 2 (2.8) 0.237a
All patients with complications (all grades) 60 (67.4) 50 (69.4) 0.783a
Postoperative mortality
30-day mortality 2 (2.2) 3 (4.2) 0.486a
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extended CROSS criteria and the factors with a P value
lower than 0.10 in the univariate analysis. Independent
prognostic factors for OS in the multivariate Cox regres-
sion analysis were ypN (P = 0.023), ypT (P = 0.043), and
group 2 (P = 0.008). In a multivariate Cox regression
analysis that assessed each eligibility criterion separately,
only celiac lymph node involvement [hazard ratio (HR)
3.583; 95% CI 1.884–6.814; P = 0.000] was an indepen-
dent prognostic factor for OS.
Disease-Free Survival
The difference in DFS between group 1 and 2 approa-
ched significance (P = 0.073; Fig. 1b), with a median of
42.5 months (95% CI 15.7–69.4 months) in group 1 and
18.2 months (95% CI 7.4–28.9 months) in group 2.
Table 4 displays the extended CROSS criteria and the
factors with a P value lower than 0.10 in the univariate
analyses, as well as the independent prognostic factors in
the multivariate Cox regression analysis for DFS. Gender
(P = 0.024), LN ratio (P = 0.001), squamous cell carci-
noma (P = 0.031), and group 2 (P = 0.027) were
independent prognostic factors for DFS. A closer look at
specific subgroups of group 2 with multivariate Cox
regression analysis showed that only celiac lymph node
metastasis was an independent prognostic factor for DFS
(HR 3.741; CI 1.822–7.680; P = 0.000).
Comparison of Survival Between the Extended CROSS
and dCRT Reference Group
Supplementary Table 1 depicts the characteristics of the
dCRT and extended CROSS group. The dCRT group
(n = 80) and the extended CROSS group (n = 72) differed
in cT stage (P = 0.001), cN stage (P = 0.000), squamous
cell carcinoma (P = 0.006), tumor location (P = 0.001),
age (P = 0.021), and WHO performance status
(P = 0.007). The patients in the extended CROSS group
showed an increased OS (P = 0.010; Fig. 1g) with the log-
rank test but not in the Cox-regression model
(Supplementary Table 2) that contained possible con-
founders. The number of complications grade C 3 did not
differ between the two groups (P = 0.115).
DISCUSSION
Several randomized studies, including the CROSS
study, have shown that nCRT increases both OS and DFS
for EC patients with locoregional disease compared with
surgery alone.1,7 Moreover, pathologic complete response
rates of approximately 30% are commonly observed after
nCRT.1 Extending the original criteria for CROSS nCRT is
a logical step to improvement of survival in locally
advanced EC.
In this study, we assessed the impact of extended eli-
gibility criteria for nCRT on toxicities, OS, and DFS in
these patients. No difference was found in the toxicity rates
between the patients in group 1 (original CROSS criteria)
and group 2 (extended CROSS criteria). However, the OS
and DFS in group 2 were significantly lower in the mul-
tivariate Cox regression analysis.
Schrauwen et al.5 (n = 116) found that the extended
inclusion criteria based on tumor length greater than 8 cm
(n = 7) and age over 75 years (n = 9) had no influence on
the complication rates but were prognostic for OS with the
log-rank test. However, interpreting these results is difficult
due to the low number of patients, the absence of multi-
variate analysis, and the absence of celiac lymph node
metastases in the analysis.5
The overall rate of toxicity (grade C 3) or blood trans-
fusion was not significantly higher in group 2 (24.7%) than
in group 1 (36.1%) (P = 0.117). The incidences of severe
leukopenia (grade C 3) in group 1 (15.7%) and group 2
(16.7%) were somewhat higher than the 6% in the original
CROSS trial but within the range of 3–24% in the
literature.1,8,9 Furthermore, the observed rates of throm-
bocytopenia grade 3 or higher of 1.1% in group 1 and 0%
in group 2 correspond well with the 1% rate of thrombo-
cytopenia in the CROSS trial. The 30-day mortality rates in









90-day mortality 6 (6.7) 7 (9.7) 0.492a
nCRT neoadjuvant chemoradiotherapy, NA not applicable
a Likelihood ratio
b Pneumonia, atelectasis, respiratory insufficiency, acute respiratory distress syndrome, pleural effusion, pneumothorax and/or pulmonary
embolism
c Arrhythmia and/or myocardial infarction




































Celiac lymph node metastasis
No celiac lymph nodes
P = 0.000*
Celiac lymph node metastasis
No celiac lymph nodes
P = 0.000*
Extended eligibility criteria









































































































FIG. 1 The overall and disease-free survival in patients that met the
original CROSS criteria or the extended CROSS eligibility criteria (a,
b), in patients with or without celiac lymph node metastases (c, d),
and in patients that met the original CROSS criteria or the extended
CROSS eligibility criteria without celiac lymph node metastases (e,
f). And the overall survival in patients that met the extended CROSS
eligibility criteria or patients from a definitive chemoradiotherapy
reference group (g)
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with the mortality rate of 2% in the original CROSS study.1
Thus, the CROSS nCRT schedule in group 2 is not asso-
ciated with significantly higher hematologic or non-
hematologic toxicity and can be safely applied in the
extended patient category.
The 5-year OS of 47% (median 48.6 months) found in
the Dutch randomized CROSS trial is comparable with the
43% (median 37.3 months) in our group 1.1,2 Conversely,
the extended criteria group 2 had a remarkably lower
5-year OS of 23% (median, 17.2 months). The median
survival after noninvasive dCRT, an alternative for patients
with considerable comorbidity, is 16–21 months, raising
the question whether dCRT is worth considering for the
extended patient category.10–13 Nevertheless, direct com-
parison of survival rates in the dCRT and extended CROSS
group is not possible because dCRT studies also included
irresectable tumors and inoperable patients.
In the included dCRT reference group, we found a
significantly lower OS (P = 0.010) with the univariate log-
rank test. However, this test does not correct for baseline
differences (gender, cTN stage, tumor localization, tumor
length, histology, and age) between the extended nCRT
group and the dCRT group. Hence, a multivariate Cox
regression analysis containing these confounding variables
was performed in which the OS did not differ (P = 0.445)
between the extended CROSS group and the dCRT group.
This suggests that the difference in survival curves might
be caused by baseline differences between the groups
rather than superiority of nCRT followed by surgery over
dCRT.
TABLE 3 Prognostic factors on uni- and multivariate Cox regression analysis for overall survival
HR (95% CI) P value
Univariate analysis
Group 2 1.802 (1.200–2.707) 0.005
Celiac lymph node metastasis 3.969 (2.188–7.198) 0.000
Cardia growth 2–4 cm 1.329 (0.721–2.452) 0.362
Length[8 cm 1.217 (0.699–2.118) 0.488
Weight loss[10% 1.407 (0.892–2.217) 0.142









R1 resection 3.266 (1.543–6.912) 0.002
LN ratio ([0.2 LN ?) 2.29 (1.437–4.105) 0.001
Perineural growth 2.076 (1.314–3.279) 0.002











HR hazard ratio, CI confidence interval, ypT pathologic T stage, ypN pathologic lymph node stage, LN lymph node
a Variables with P\ 0.10 in the univariate analysis were included in the multivariate analysis
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Several studies found a comparable outcome in patients
with celiac and regional lymph node metastasis. Celiac
lymph node metastases are therefore currently classified as
regional lymph nodes (N ?), whereas previous classifica-
tion systems regarded them as distant (M1a).14–16 In the
current study, the presence of tumor-positive celiac lymph
nodes (n = 13) was the only extended eligibility criterion
with an independent prognostic value. We compared the
survival of patients with celiac lymph node metastases in
the extended CROSS group (n = 13) with M1a patients in
the dCRT group (the latter involving both irre-
sectable higher mediastinal and celiac nodes; n = 15) and
found no difference in survival (P = 0.336). However, the
groups were too small for a solid conclusion. Davies et al.10
found that celiac lymph node metastasis (determined by
endoscopic ultrasound) was not prognostic for OS after
dCRT, which was confirmed by Gwynne et al.13 However,
further research seems necessary to elucidate the value of
dCRT for patients with celiac lymph node metastasis,
probably in a randomized controlled trial or a large retro-
spective study.
The potential limitations of our study include the small
sample size, especially the subgroup of patients with celiac
lymph node metastases (n = 13). Moreover, two of these
patients died within 90 days after surgery, which may have
influenced the OS. Another potential weakness is that we
included only patients who received surgery, whereas
approximately 8% experience interval metastases between
nCRT and surgery.17
In conclusion, extension of the original CROSS inclu-
sion criteria for nCRT followed by surgery in EC did not
influence the toxicity rate, indicating safe application of the
TABLE 4 Prognostic factors on uni- and multivariate Cox regression analysis for disease-free survival
HR (95% CI) P value
Univariate analysis
Group 2 1.509 (0.959–2.375) 0.075
Celiac lymph node metastasis 3.898 (1.923–7.904) 0.000
Cardia growth 2–4 cm 1.454 (0.742–2.849) 0.275
Length[8 cm 1.103 (0.580–2.097) 0.764
Weight loss[10% 1.229 (0.720–2.096) 0.450
Female 0.484 (0.255–0.920) 0.027
Squamous cell carcinoma 0.366 (0.167–0.802) 0.012











R1 resection 4.389 (2.043–9.431) 0.000
LN ratio ([0.2 LN ?) 3.106 (1.758–5.489) 0.000
Perineural growth 1.694 (0.993–2.890) 0.053
Lymphangio-invasion 1.940 (1.131–3.327) 0.016
Multivariate analysisa
Female 0.474 (0.248–0.907) 0.024
Squamous cell carcinoma 0.413 (0.185–0.923) 0.031
Group 2 1.685 (1.061–2.676) 0.027
LN ratio ([0.2 LN ?) 2.712 (1.524–4.826) 0.001
HR hazard ratio, CI confidence interval, cT clinical T stage, ypT pathologic T stage, ypN pathologic lymph node stage, LN lymph node
PUB1: OK not to spell PET/CT here? Spelling here would be cumbersome
a Variables with P\ 0.10 in the univariate analysis were included in the multivariate analysis
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CROSS nCRT regimen in the extended patient category.
However, the OS in the extended CROSS group was sig-
nificantly lower than in the standard CROSS group and did
not differ significantly from the OS in the dCRT reference
group in the multivariate Cox regression analysis. This
implies that the additional value of nCRT followed by
surgery compared with dCRT in the extended CROSS
group might be limited. The findings of this study support
further research regarding the strategy to extend the orig-
inal CROSS criteria for nCRT in patients with locally
advanced EC, and should focus more on patients with
celiac node metastases.
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